Lupus & antiphospholipid syndrome
Burden of herpes zoster and recombinant zoster vaccine willingness in systemic lupus erythematosus: A single-center cohort study
Authors' conclusion
HZ was common and frequently recurrent in this Japanese SLE cohort. Ever use of azathioprine and renal dysfunction were associated with HZ development, while willingness to receive RZV was low.
Study context
- Population
- Consecutive adult outpatients with systemic lupus erythematosus (SLE), single centre, December 2024 to June 2025
- Participants
- 170 outpatients
- Exposure
- HZ0 vs HZ1 vs herpes zoster (HZ)≥2
- Outcome
- HZ after SLE diagnosis
Methodological detailssingle-center, combined with a cross-sectional survey, multivariable logistic regression
- Single-center
- Combined with a cross-sectional survey
- Multivariable logistic regression
Main finding
As reported in the abstract
At least one HZ episode after SLE diagnosis
73
43%
Recurrent HZ (of those with HZ)
29
40%
HZ episodes reported (at least) over 3138 person-years
102
Minimum incidence per 1000 person-years
32.5
Observational data: associations, not effects.
Further findings
Factors associated with HZ development (multivariable analysis)
| OR (95% CI) | ||
|---|---|---|
| Ever use of AZA | 2.74 (1.03–7.29) | |
| Renal dysfunction | 2.59 (1.04–6.48) | |
| 0.10.31310Odds ratio (log scale) |
Willingness to receive recombinant zoster vaccine (RZV)
- Willing
- 31 (20%)
- Unwilling
- 47 (30%)
- Unsure
- 81 (50%)
- Attitude data available for 159 patients
Original publication
Burden of herpes zoster and recombinant zoster vaccine willingness in systemic lupus erythematosus: A single-center cohort study. Lupus. Published 28 September 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →